会員登録
ログイン
【4894】クオリプス
再生医療等製品、特定細胞加工物の研究、開発、製造、販売など
類似企業：
【業界1位】
小野薬品工業
【業界1位】
小野薬品工業
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027.03 | 2026/08/13 | Q1予 | 540 | → | 0.0% | 0.0% | -1,030 | → | 0.0% | +28.0% | -580 | → | 0.0% | +58.6% | -570 | → | 0.0% | +59.0% |
| 2027.03 | 2026/07/28 | 修正予 | 540 | - | - | - | -1,030 | ↑ | +28.0% | +28.0% | -580 | ↑ | +58.6% | +58.6% | -570 | ↑ | +59.0% | +59.0% |
| 2027.03 | 2026/05/15 | 当初予 | - | - | - | - | -1,430 | - | - | - | -1,400 | - | - | - | -1,390 | - | - | - |
| 2026.03 | 2026/05/15 | 実 | 212 | → | 0.0% | -64.1% | -1,081 | ↓ | -5.6% | -20.8% | -1,028 | ↓ | -4.8% | -16.4% | -1,022 | ↓ | -4.0% | -15.0% |
| 2026.03 | 2026/02/13 | Q3予 | 212 | ↓ | -64.1% | -64.1% | -1,024 | ↓ | -14.4% | -14.4% | -981 | ↓ | -11.1% | -11.1% | -983 | ↓ | -10.6% | -10.6% |
| 2026.03 | 2025/11/13 | Q2予 | 590 | → | 0.0% | 0.0% | -895 | → | 0.0% | 0.0% | -883 | → | 0.0% | 0.0% | -889 | → | 0.0% | 0.0% |
| 2026.03 | 2025/08/13 | Q1予 | 590 | → | 0.0% | 0.0% | -895 | → | 0.0% | 0.0% | -883 | → | 0.0% | 0.0% | -889 | → | 0.0% | 0.0% |
| 2026.03 | 2025/05/14 | 当初予 | 590 | - | - | - | -895 | - | - | - | -883 | - | - | - | -889 | - | - | - |
| 2025.03 | 2025/05/14 | 実 | 175 | → | 0.0% | +775.0% | -590 | ↑ | +15.8% | +51.0% | -642 | ↑ | +14.4% | +46.6% | -644 | ↑ | +14.6% | +46.6% |
| 2025.03 | 2025/02/13 | Q3予 | 175 | ↑ | +1.2% | +775.0% | -701 | ↑ | +24.1% | +41.7% | -750 | ↑ | +24.2% | +37.6% | -754 | ↑ | +24.1% | +37.5% |
| 2025.03 | 2024/11/14 | Q2予 | 173 | ↑ | +765.0% | +765.0% | -924 | ↑ | +23.2% | +23.2% | -989 | ↑ | +17.7% | +17.7% | -993 | ↑ | +17.7% | +17.7% |
| 2025.03 | 2024/08/13 | Q1予 | 20 | → | 0.0% | 0.0% | -1,203 | → | 0.0% | 0.0% | -1,202 | → | 0.0% | 0.0% | -1,206 | → | 0.0% | 0.0% |
| 2025.03 | 2024/05/13 | 当初予 | 20 | - | - | - | -1,203 | - | - | - | -1,202 | - | - | - | -1,206 | - | - | - |
| 2024.03 | 2024/05/13 | 実 | 23 | → | 0.0% | -89.3% | -588 | ↑ | +21.9% | +51.4% | -627 | ↑ | +20.8% | +49.7% | -632 | ↑ | +20.6% | +49.4% |
| 2024.03 | 2024/02/13 | Q3予 | 23 | ↓ | -28.1% | -89.3% | -753 | ↑ | +28.9% | +37.8% | -792 | ↑ | +27.9% | +36.4% | -796 | ↑ | +27.6% | +36.3% |
| 2024.03 | 2023/11/10 | Q2予 | 32 | ↓ | -85.1% | -85.1% | -1,059 | ↑ | +12.5% | +12.5% | -1,099 | ↑ | +11.8% | +11.8% | -1,100 | ↑ | +11.9% | +11.9% |
| 2024.03 | 2023/08/10 | 当初予 | 215 | - | - | - | -1,210 | - | - | - | -1,246 | - | - | - | -1,249 | - | - | - |
